Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
microRNA-26a is a naturally occurring small non-coding RNA that functions as a potent tumor suppressor in various malignancies, most notably hepatocellular carcinoma (HCC). It exerts its therapeutic effect by binding to the 3' untranslated regions (UTRs) of specific oncogenic messenger RNAs, leading to their degradation or translational inhibition. Key targets include cell cycle regulators such as Cyclin D2 (CCND2) and Cyclin E2 (CCNE2), as well as the epigenetic modulator EZH2. In HCC, miR-26a expression is frequently lost, and its restoration via nanoparticle-mediated delivery or viral vectors has demonstrated significant anti-tumor activity in preclinical models by inducing cell cycle arrest and apoptosis. Research is currently focused on optimizing delivery systems to overcome the rapid degradation and poor cellular uptake of naked miRNA.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on microRNA-26a.